Left to right: Marcia J. Avedon, Ph.D., 41, senior vice president, Human Resources Judy C. Lewent, 54, executive vice president, chief financial officer and president, Human Health-Asia Bradley T. Sheares, Ph.D., 46, president, U.S. Human Health Peter S. Kim, Ph.D., 44, president, Merck Research Laboratories Per Wold-Olsen, 55, president, Human Health-Europe, Middle East and Africa Raymond V. Gilmartin, 62, chairman, president and chief executive officer Adel A.F. Mahmoud, M.D., Ph.D., 61, president, Merck Vaccine Division Kenneth C. Frazier, 48, senior vice president and general counsel Robert H. Boisclair, 55, acting president, Merck Manufacturing Division Margaret G. McGlynn, 43, president, U.S. Human Health David W. Anstice, 54, president, Human Health   Changes to Management Committee announced in 2002 2002 was a year of change for several key Merck executives. Edward M. Scolnick stepped down after an extraordinary tenure as president of the Merck Research Laboratories. In December, Dr. Scolnick announced his intention to return to the laboratory bench to pursue his commitment to research new treatment approaches in severe mental disorders. Dr. Scolnick is succeeded by Peter S. Kim, a renowned molecular biologist recruited by Merck from the Massachusetts Institute of Technology.      Two other talented leaders retired from Merck’s Management Committee in 2002 after outstanding service to the Company. Bernard J. Kelley retired as president of the Merck Manufacturing Division, and Paul R. Bell retired as president, Human Health-Asia Pacific.      Judy C. Lewent took on responsibility as president, Human Health-Asia in addition to her ongoing duties as executive vice president and chief financial officer. David W. Anstice, formerly president, Human Health-The Americas, is now president, Human Health, responsible for Latin America, Canada, Australia, New Zealand, Japan and our joint venture relationship with Schering-Plough. Bradley T. Sheares, president, U.S. Human Health (USHH), took on new responsibility for primary care products, while Margaret G. McGlynn assumed new responsibilities as president, USHH, for our hospital and specialty product franchises. In addition, Marcia J. Avedon was promoted to senior vice president, Human Resources, succeeding Wendy L. Yarno, who was named executive vice president, Worldwide Human Health Marketing.      These changes have resulted in strong, experienced individuals assuming key leadership roles for the Company. The ongoing strength and continuity of our leadership is testimony to the abilities of Merck’s people.   Left to right: William M. Daley, 54, president, SBC Communications, Inc. Johnnetta B. Cole, Ph.D., 66, president, Bennett College Lawrence A. Bossidy, 68, retired chairman and chief executive officer, Honeywell International Inc. Thomas E. Shenk, Ph.D., 56, Elkins professor and chairman, Department of Molecular Biology, Princeton University William G. Bowen, Ph.D., 69, president, The Andrew W. Mellon Foundation   Raymond V. Gilmartin, 62, chairman, president and chief executive officer, Merck & Co., Inc. since 1994 Heidi G. Miller, Ph.D., 49, executive vice president and chief financial officer, Bank One Corporation William N. Kelley, M.D., 63, professor, Medicine, Biochemistry and Biophysics, University of Pennsylvania School of Medicine Samuel O. Thier, M.D., 65, professor, Medicine and professor, Health Care Policy, Harvard Medical School Anne M. Tatlock, 63, chairman and chief executive officer, Fiduciary Trust Company International William B. Harrison, Jr., 59, chairman and chief executive officer, J.P. Morgan Chase & Co.